Abiopharma

News list

Ionis Pharmaceuticals Inc (IONS)

Event
June 21, 2022, 10:03 UTC

(90% Positive) IONIS PHARMACEUTICALS, INC. (IONS) Provides Update on treatments for a range of unmet medical needs

Full text

News bot Oct. 2, 2025, 8:19 a.m.

📋 IONIS PHARMACEUTICALS, INC. (IONS) - Clinical Trial Update

Filing Date: 2022-06-21

Accepted: 2022-06-21 06:03:49

Event Type: Clinical Trial Update

Event Details:

Ionis Pharmaceuticals Inc (IONS) Announces Clinical Trial Update Ionis Pharmaceuticals Inc (IONS) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: treatments
Diseases/Conditions: a range of unmet medical needs
Clinical Stage: Phase 3
Collaboration: AstraZeneca

🔬 Clinical Development Pipeline (IONIS PHARMACEUTICALS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Placebo	DRUG	Phase PHASE3	Angelman Syndrome	ClinicalTrials.gov
ION582	DRUG	Phase PHASE3	Angelman Syndrome	ClinicalTrials.gov
Sham procedure	PROCEDURE	Phase PHASE1	Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome	ClinicalTrials.gov
ION440	DRUG	Phase PHASE1	Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Ionis Pharmaceuticals Inc
CIK: 0000874015
Ticker Symbol: IONS
Period End Date: 2022-06-21
Document Type: 8-K